完全切除早期非小细胞肺癌的辅助度伐利尤单抗治疗
BR.31 试验评估完全切除的 IB(≥4 cm)至 IIIA 期 NSCLC 患者术后辅助度伐利尤单抗对比安慰剂的疗效。共随机 1415 例,其中 1219 例为 EGFR-/ALK-;
要点
- 完全切除早期 NSCLC 术后辅助度伐利尤单抗未改善 DFS。
- 3-4 级不良事件度伐利尤单抗组 26%,安慰剂组 20%。
核心结论
- 在 EGFR-/ALK- 的完全切除早期 NSCLC 中,辅助度伐利尤单抗对比安慰剂未改善 DFS,无论 PD-L1 状态如何。
研究设计与样本
- 加拿大癌症试验组 BR.31 随机对照试验,完全切除 IB(≥4 cm)至 IIIA 期 NSCLC 患者按 2:1 随机接受度伐利尤单抗 20 mg/kg 或安慰剂 20 mg/kg 每 4 周一次共 12 周期。
- 共随机 1415 例,其中 1219 例(86%)为 EGFR-/ALK- 肿瘤:度伐利尤单抗组 815 例,安慰剂组 404 例。
- 主要终点为研究者评估的 DFS,主要分析人群为 PD-L1 TC≥25% 且 EGFR-/ALK- 亚组。
主要发现
- 次要分析人群(PD-L1 TC≥1% 且 EGFR-/ALK-、全部 EGFR-/ALK-)DFS 亦无差异。
- 3-4 级不良事件度伐利尤单抗组 26%,安慰剂组 20%。
关键数值与推荐
- 3-4 级不良事件发生率:度伐利尤单抗组 26%,安慰剂组 20%。
临床怎么用
- 完全切除早期 NSCLC 术后辅助度伐利尤单抗未显示 DFS 获益,不支持在该人群常规使用。
- EGFR-/ALK- 且无论 PD-L1 状态,辅助度伐利尤单抗均未改善 DFS。
局限性
- 主要分析人群为 PD-L1 TC≥25% 且 EGFR-/ALK- 亚组,非全部随机人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Adjuvant immunotherapy improved patient outcomes in two trials in completely resected non-small cell lung cancer (NSCLC), but with conflicting primary end point results. The Canadian Cancer Trials Group BR.31 trial evaluated adjuvant durvalumab in completely resected early-stage NSCLC. METHODS: Following resection of stage IB (≥4 cm) to IIIA NSCLC (American Joint Committee on Cancer 7th Edition) and optional adjuvant chemotherapy, patients were randomly assigned 2:1 to durvalumab 20 mg/kg or placebo 20 mg/kg once every 4 weeks for 12 cycles. Random assignment was stratified by stage, extent of nodal dissection, tumor cell (TC) PD-L1 expression, adjuvant chemotherapy use, and center. The primary end point was investigator-assessed disease-free survival (DFS). Secondary outcomes included overall survival (OS), adverse events, and quality of life. The primary analysis was in the subgroup with cancers that had a PD-L1 TC expression ≥25%, no common activating EGFR mutations (EGFR-), and no ALK gene rearrangements (ALK-). Secondary analyses in hierarchical order included DFS in the subgroup whose tumors were EGFR-/ALK- with PD-L1 TC ≥1%, followed by all patients whose tumors were EGFR-/ALK-, followed by OS in the same primary and secondary subgroups in the same hierarchical order. RESULTS: Of 1,415 patients randomly assigned, 1,219 (86%) had EGFR-/ALK- tumors: 815 randomly assigned to durvalumab and 404 to placebo. With a median follow-up of 60 months, there were no differences in DFS between patients assigned durvalumab (316) versus placebo (161) in the primary population (stratified hazard ratio [HR], 0.93 [95% CI, 0.71 to 1.25]; P = .64) or in the secondary populations. Grade 3 to 4 adverse events were higher in durvalumab-treated patients (D = 26% v P = 20%). CONCLUSION: Adjuvant durvalumab following complete resection was not associated with improvement in DFS compared with placebo in EGFR-/ALK- NSCLC, regardless of PD-L1 status.
引用
- Goss GD, Darling GE, Westeel V, et al. Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer. J Clin Oncol. 2026. PMID: 41529222. doi:10.1200/JCO-25-01828
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。